XML 24 R15.htm IDEA: XBRL DOCUMENT
v3.24.3

Note 8 - Segment and Geographic Data | 9 Months Ended
--- | ---
Sep. 30, 2024
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | NOTE 8 — SEGMENT AND GEOGRAPHIC DATA The Company conducts its business through two reportable segments: Dental and Medical. These segments offer different products and services to different customer bases. The Company provides general corporate services to its segments; however, these services are not considered when making operating decisions and assessing segment performance. These services are reported under “Corporate Services” below and these include costs associated with executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities and public company compliance. The following tables present information about our reportable and operating segments:
|  | For the three months ended September 30, |  |  | For the nine months ended September 30, |
Sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net Sales: |  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Dental |  | $ | 2,466,405 |  |  | $ | 2,053,284 |  |  | $ | 6,542,594 |  |  | $ | 7,556,848 |
Medical |  |  | 47,400 |  |  |  | 6,000 |  |  |  | 73,820 |  |  |  | 10,000 |
Total net sales |  | $ | 2,513,805 |  |  | $ | 2,059,284 |  |  | $ | 6,616,414 |  |  | $ | 7,566,848 |
Operating Income (Loss): |  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Dental |  | $ | 705,427 |  |  | $ | 458,474 |  |  | $ | 1,524,177 |  |  | $ | 1,699,349 |
Medical |  |  | (356,555 | ) |  |  | (740,087 | ) |  |  | (1,376,294 | ) |  |  | (2,425,913 | )
Corporate |  |  | (1,818,051 | ) |  |  | (1,225,092 | ) |  |  | (4,862,553 | ) |  |  | (4,400,369 | )
Total operating loss |  | $ | (1,469,179 | ) |  | $ | (1,506,705 | ) |  | $ | (4,714,670 | ) |  | $ | (5,126,933 | )
Depreciation and Amortization: |  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Dental |  | $ | - |  |  | $ | 1,051 |  |  | $ | - |  |  | $ | 3,439 |
Medical |  |  | - |  |  |  | 585 |  |  |  | - |  |  |  | 2,247 |
Corporate |  |  | 8,574 |  |  |  | 14,260 |  |  |  | 28,735 |  |  |  | 44,112 |
Total depreciation and amortization |  | $ | 8,574 |  |  | $ | 15,896 |  |  | $ | 28,735 |  |  | $ | 49,798 |
Income (loss) before taxes and equity in earnings of affiliates: |  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Dental |  | $ | 705,433 |  |  | $ | 458,504 |  |  | $ | 1,523,209 |  |  | $ | 1,698,790 |
Medical |  |  | (356,555 | ) |  |  | (742,004 | ) |  |  | (1,376,576 | ) |  |  | (2,431,502 | )
Corporate |  |  | (1,810,049 | ) |  |  | (1,192,605 | ) |  |  | (2,824,695 | ) |  |  | (4,291,552 | )
Total income (loss) before taxes and equity in earnings of affiliate |  | $ | (1,461,171 | ) |  | $ | (1,476,105 | ) |  | $ | (2,678,062 | ) |  | $ | (5,024,264 | )
Total Assets |  | September 30, 2024 |  |  | December 31, 2023 |  |  |  |  |  |  |  |  |
Dental |  | $ | 5,528,106 |  |  | $ | 4,866,786 |  |  |  |  |  |  |  |  |
Medical |  |  | 220,698 |  |  |  | 345,194 |  |  |  |  |  |  |  |  |
Corporate |  |  | 5,426,114 |  |  |  | 6,159,532 |  |  |  |  |  |  |  |  |
Total assets |  | $ | 11,174,918 |  |  | $ | 11,371,512 |  |  |  |  |  |  |  |  |
The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by business segment product category:
|  | Three Months Ended September 30, 2024 |  |  | Three Months Ended September 30, 2023 |
Domestic: US |  | Dental |  |  | Medical |  |  | Grand Total |  |  | Dental |  |  | Medical |  |  | Grand Total |
Instruments |  | $ | 179,699 |  |  | $ | 1,000 |  |  | $ | 180,699 |  |  | $ | 230,615 |  |  | $ | - |  |  | $ | 230,615 |
Handpieces |  |  | 1,029,116 |  |  |  | 11,400 |  |  |  | 1,040,516 |  |  |  | 1,007,930 |  |  |  | - |  |  |  | 1,007,930 |
Accessories |  |  | 5,501 |  |  |  | - |  |  |  | 5,501 |  |  |  | 14,822 |  |  |  | - |  |  |  | 14,822 |
Grand Total |  | $ | 1,214,316 |  |  | $ | 12,400 |  |  | $ | 1,226,716 |  |  | $ | 1,253,367 |  |  | $ | - |  |  | $ | 1,253,367 |
International: Rest of World |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Instruments |  | $ | 261,466 |  |  | $ | 32,500 |  |  | $ | 293,966 |  |  | $ | 88,019 |  |  | $ | - |  |  | $ | 88,019 |
Handpieces |  |  | 961,089 |  |  |  | 2,500 |  |  |  | 963,589 |  |  |  | 700,697 |  |  |  | 6,000 |  |  |  | 706,697 |
Accessories |  |  | 29,534 |  |  |  | - |  |  |  | 29,534 |  |  |  | 11,201 |  |  |  | - |  |  |  | 11,201 |
Grand Total |  | $ | 1,252,089 |  |  | $ | 35,000 |  |  | $ | 1,287,089 |  |  | $ | 799,917 |  |  | $ | 6,000 |  |  | $ | 805,917 |
Total Product Sales |  | $ | 2,466,405 |  |  | $ | 47,400 |  |  | $ | 2,513,805 |  |  | $ | 2,053,284 |  |  | $ | 6,000 |  |  | $ | 2,059,284 |
|  | Nine Months Ended September 30, 2024 |  |  | Nine Months Ended September 30, 2023 |
Domestic: US |  | Dental |  |  | Medical |  |  | Grand Total |  |  | Dental |  |  | Medical |  |  | Grand Total |
Instruments |  | $ | 588,250 |  |  | $ | 2,000 |  |  | $ | 590,250 |  |  | $ | 726,104 |  |  | $ | - |  |  | $ | 726,104 |
Handpieces |  |  | 3,245,673 |  |  |  | 35,400 |  |  |  | 3,281,073 |  |  |  | 3,277,830 |  |  |  | - |  |  |  | 3,277,830 |
Accessories |  |  | 37,168 |  |  |  | - |  |  |  | 37,168 |  |  |  | 59,336 |  |  |  | - |  |  |  | 59,336 |
Grand Total |  | $ | 3,871,091 |  |  | $ | 37,400 |  |  | $ | 3,908,491 |  |  | $ | 4,063,270 |  |  | $ | - |  |  | $ | 4,063,270 |
International: Rest of World |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Instruments |  | $ | 668,728 |  |  | $ | 32,500 |  |  | $ | 701,228 |  |  | $ | 961,224 |  |  | $ | - |  |  | $ | 961,224 |
Handpieces |  |  | 1,965,683 |  |  |  | 3,920 |  |  |  | 1,969,603 |  |  |  | 2,222,707 |  |  |  | 10,000 |  |  |  | 2,232,707 |
Accessories |  |  | 37,092 |  |  |  | - |  |  |  | 37,092 |  |  |  | 39,647 |  |  |  | - |  |  |  | 39,647 |
Grand Total |  | $ | 2,671,503 |  |  | $ | 36,420 |  |  | $ | 2,707,923 |  |  | $ | 3,223,578 |  |  | $ | 10,000 |  |  | $ | 3,233,578 |
International: China |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Instruments |  | $ | - |  |  | $ | - |  |  | $ | - |  |  | $ | 270,000 |  |  | $ | - |  |  | $ | 270,000 |
Handpieces |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Accessories |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Grand Total |  | $ | - |  |  | $ | - |  |  | $ | - |  |  | $ | 270,000 |  |  | $ | - |  |  | $ | 270,000 |
Total Product Sales |  | $ | 6,542,594 |  |  | $ | 73,820 |  |  | $ | 6,616,414 |  |  | $ | 7,556,848 |  |  | $ | 10,000 |  |  | $ | 7,566,848 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration